123 results
Page 3 of 7
8-K
EX-99.1
hb7g6yn
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
oxxcrim0m wnp
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-99.1
egsvdsvb mfruabvhj
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
EX-99.2
b3mz9d5s7oh 1u16
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
7j523uf7221 a0q1h
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
yep07ycaf442s
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.2
orndey523m6e
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
mqcrlg c0o
2 Mar 21
Regulation FD Disclosure
8:00am
424B5
1js9jeg3ksh6st
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-99.1
dfobf
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.2
m9w0ygn3clyz3s9vcra
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
e91 xz0udw01ayl4
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
dwiwzj9u7sy7hls9w8uq
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
EX-99.1
atd4p
5 Nov 20
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:31pm
8-K
a9q8jz wff00orne10
17 Sep 20
Departure of Directors or Certain Officers
7:05am
8-K
02bn6 m7ggrssg1b
15 Sep 20
Other Events
4:11pm